Literature DB >> 9071622

A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey.

O Ozgoztasi1, I Baydar.   

Abstract

An open-labeled, randomized clinical trial to evaluate the efficacy of paromomycin ointment as compared with ketoconazole was conducted on seventy-two patients of both sexes and different ages with the confirmed diagnosis of cutaneous leishmaniasis (CL). All patients had a complete clinical evaluation for other diseases. Patients were excluded if they were pregnant or nursing or if they had serious concomitant diseases. Patients were divided randomly into two treatment groups: in the first group 40 patients were treated with an ointment containing 15% paromomycin sulfate and 12% methylbenzothonium chloride in white soft paraffin (labeled as p-ointment by El-On1) twice daily for 15 days. Treated lesions were left uncovered. The second group consisted of 32 patients who received ketoconazole 400 mg/day orally for 30 days. This dosage was reduced to 200 mg/day for patients below 12 years of age. In all cases the diagnosis was based on positive smear and/or culture. Direct smears were prepared from the exudate obtained by a small incision made at the edge of the lesion with a sterile surgical blade or lancet and stained using the Giemsa method for leishmania bodies (Fig 1). In smear negative and suspected cases aspirates taken by puncturing the lesions were inoculated onto NNN (Novy, McNeal, Nicolle) medium for culture. The cultures were incubated at 28 degrees C and the development of motile promastigotes was observed. Clinical and parasitological evaluations of the patients were performed at the end of the treatment period and 4 weeks post-treatment. A cure was defined as complete healing and disappearance of the lesion or reversible hypopigmentation at the site of lesion. Incomplete or partial improvement was defined as a reduction in the size of a lesion and the absence of parasites on smear or culture. A treatment failure was defined as the absence of any changes in the lesion and persistence of parasites on smear or culture.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071622     DOI: 10.1046/j.1365-4362.1997.00022.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  13 in total

1.  Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan.

Authors:  Yoav Keynan; Oscar E Larios; Marni C Wiseman; Marie Plourde; Marc Ouellette; Ethan Rubinstein
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

Review 2.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

Review 4.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

5.  Evidence for rosettes as an unrecognized stage in the life cycle of Leishmania parasites.

Authors:  David M Iovannisci; C Paul Plested; Gregory R Moe
Journal:  J Eukaryot Microbiol       Date:  2010-08-05       Impact factor: 3.346

Review 6.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-12-01

7.  Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.

Authors:  Dae Hyun Kim; Hye Jin Chung; Joachim Bleys; Reza F Ghohestani
Journal:  PLoS Negl Trop Dis       Date:  2009-02-17

8.  WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.

Authors:  Afif Ben Salah; Pierre A Buffet; Gloria Morizot; Nathalie Ben Massoud; Amor Zâatour; Nissaf Ben Alaya; Nabil Bel Haj Hamida; Zaher El Ahmadi; Matthew T Downs; Philip L Smith; Koussay Dellagi; Max Grögl
Journal:  PLoS Negl Trop Dis       Date:  2009-05-05

9.  Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006.

Authors:  Farrokh Modabber; Pierre A Buffet; Els Torreele; Geneviéve Milon; Simon L Croft
Journal:  Kinetoplastid Biol Dis       Date:  2007-04-24

Review 10.  Drug repurposing and human parasitic protozoan diseases.

Authors:  Katherine T Andrews; Gillian Fisher; Tina S Skinner-Adams
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-03-24       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.